Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells

References

• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–3356.
   PubMed Web of Science ®Google Scholar
• Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003;101:2940–2954.
   PubMed Web of Science ®Google Scholar
• Heaney NB, Holyoake TL. Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol 2007;25:66–75.
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007;44:S4–S14.
   PubMed Web of Science ®Google Scholar
• Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;21:1–8.
   Google Scholar
• Li G, Sun T, Su Y, et al Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol 2008;89:9–17.
   PubMed Web of Science ®Google Scholar
• Orth C, Moriggl R, Tsareva SA, et al Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005;7:545–555.
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008;11:3367–3377.
   Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, et al Stat3 as an oncogene. Cell 1999;98:295–303.
   PubMed Web of Science ®Google Scholar
• Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008;7:3169–3175.
   PubMed Web of Science ®Google Scholar
• Cockrell AS, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol 2007;36:184–204.
   PubMed Web of Science ®Google Scholar
• Matta H, Hozayev B, Tomar R, Chugh P, Chaudhary PM. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther 2003;2:211–212.
   PubMed Web of Science ®Google Scholar
• Kasschau KD, Carrington JC. A counterdefensive strategy of plant viruses: suppression of posttranscriptional gene silencing. Cell 1998;95:461–470.
   PubMed Web of Science ®Google Scholar
• Sambrook J, Russell D. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2001. pp 1.105–1.125.
   Google Scholar
• Ilaria RL, Van Etten. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704–31710.
   PubMed Web of Science ®Google Scholar
• Frank DA, Varticovski L. BCR/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia 1996;10:1724–1730.
   PubMed Web of Science ®Google Scholar
• Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 1997;17:6508–6516.
   PubMed Web of Science ®Google Scholar
• Coppo P, Flamant S, Veronique DM, et al BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006;134:171–179.
   PubMed Web of Science ®Google Scholar
• Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002;30:262–271.
   PubMedGoogle Scholar
• Gagarin D, Yang Z, Butler J, et al Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J Mol Cell Cardiol 2005;39:453–465.
   PubMed Web of Science ®Google Scholar
• Yang J, Chatte M, Susan MS, et al Novel roles of unphosphorylated STAT3 in oncogenesesis and transcriptional regulation. Cancer Res 2005;65:939–947.
   PubMed Web of Science ®Google Scholar
• Ivanov V, Bhoumik, Krasilnikov M, et al Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001;7:517–528.
   PubMedGoogle Scholar
• Zhang SY, Liu SC, Johnson DG, Klein-Szanto AJ. E2F-1 gene transfer enhances invasiveness of human head and neck carcinoma cell 1ines. Cancer Res 2000;60:5972–5976.
   PubMed Web of Science ®Google Scholar
• Banerjee SK, Weston AP, Zoubine MN, et al Expression of cdc2 and cyclin B1 in Helicobacter pylori-associated gastric MALT and MALT lymphoma: relationship to cell death, proliferation and transformation. Am J Pathol 2000;156:217–225.
   PubMed Web of Science ®Google Scholar
• Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003;3:23–31.
   PubMed Web of Science ®Google Scholar
• Lee SO, Lou W, Qureshi KM, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004;60:303–309.
   PubMed Web of Science ®Google Scholar
• Gao LF, Xu DQ, Wen LJ, Zhang XY, Shao YT, Zhao XJ. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin 2005;26:377–383.
   PubMed Web of Science ®Google Scholar
• Coppo P, Dusanter-Fourt I, Millot G, et al Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 2003;22:4102–4110.
   PubMed Web of Science ®Google Scholar
• Coppo P, Dusanter-Fourt I, Vainchenker W, Turhan AG. BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell Signal 2009;21:52–60.
   PubMed Web of Science ®Google Scholar